Scientists have developed a groundbreaking technology that reengineers the pig enzyme ST3Gal1 to focus on studying sugars, or glycans, found on cell surfaces. Published in Nature Communications, the study introduces a new glycan-binding enzyme named sCore2, which has the potential to revolutionize disease analysis and treatment strategies by targeting specific sugar patterns on cell surfaces. This innovative approach, led by Sriram Neelamegham, a UB Distinguished Professor, shifts ST3Gal1’s function from glycan synthesis to glycan binding, enabling a deeper understanding of the role of glycans in cell communication and disease progression.
Glycans, despite their crucial role in cellular communication, have been challenging to study due to their structural complexity and minimal immune responses. The reengineering of ST3Gal1 into sCore2 opens up new possibilities for detecting and treating diseases based on the unique sugar compositions present on cell surfaces. By utilizing mammalian surface-display technology and introducing specific mutations like H302A, scientists were able to enhance sCore2’s glycan-binding capabilities, paving the way for targeted disease analysis using fluorescent antibodies that illuminate glycan patterns. Initial tests on human blood and tissue cells revealed distinct sugar patterns on immune cells, cancerous tissues (such as breast cancer), and various organs like the spleen and pancreas.
The identification of sialylated core-2 O-glycans as potential biomarkers for cancer detection and immune cell changes underscores the transformative impact of sCore2 in disease diagnosis and personalized medicine. The study also hints at the future development of a library of customized sugar-recognizing proteins, offering a versatile toolkit for diagnosing and treating a wide range of diseases. The promising results have led to ongoing research efforts and the filing of a provisional patent application for sCore2, signaling its potential for commercialization and broader clinical applications in the future.
The collaborative efforts of UB faculty from different departments, including Biomedical Engineering, Pathology and Anatomical Sciences, and Medicine, highlight the interdisciplinary nature of this research and its implications for advancing bioinformatics and life sciences. Funded by grants from the National Institutes of Health and UB’s New York State Center of Excellence in Bioinformatics and Life Sciences, this work exemplifies the synergy between academic research and economic development initiatives in driving innovation and scientific progress. By bridging the gap in studying glycans and their significance in disease mechanisms, the reengineered enzyme sCore2 represents a significant milestone in bioengineering and opens up new possibilities for precision medicine and therapeutic interventions.
Key Takeaways:
– Reengineering the ST3Gal1 enzyme into sCore2 enables targeted analysis of sugar patterns on cell surfaces for disease detection and treatment.
– The innovative glycan-binding technology offers potential biomarkers for cancer, immune cell changes, and other disease states.
– Collaborative interdisciplinary research efforts and funding support from NIH and NYSTAR demonstrate the strategic alignment of academic research with economic development goals.
– The development of sCore2 heralds a new era in bioinformatics, personalized medicine, and the creation of customized tools for disease diagnosis and treatment.
Tags: bioinformatics
Read more on buffalo.edu